{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:55:29Z","timestamp":1792796129856,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007176","name":"Scuola Superiore Sant'Anna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007176","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The increasing recognition of cardiac amyloidosis (CA) as a cause of heart failure, coupled with advancements in therapeutic options, has underscored the need for early detection. Positron emission tomography (PET) imaging emerged as a promising non-invasive tool for diagnosing and managing CA. This review provides a comprehensive analysis of current PET imaging techniques, focusing on radiotracers, including [<jats:sup>11<\/jats:sup>C]Pittsburgh Compound B, [<jats:sup>18<\/jats:sup>F]Flutemetamol, [<jats:sup>18<\/jats:sup>F]Florbetapir, [<jats:sup>18<\/jats:sup>F]Florbetaben, [<jats:sup>18<\/jats:sup>F]-sodium fluoride, and [<jats:sup>124<\/jats:sup>I]Evuzamitide. PET imaging\u2019s ability to differentiating CA subtypes and quantify amyloid burden contributes defining prognosis and aids in monitoring treatment response. However, standardizing imaging protocols and establishing definitive diagnostic thresholds remain challenging. As PET imaging continues to evolve, it promises to improve patient outcomes by facilitating earlier diagnosis, more accurate subtype differentiation, and better treatment monitoring in CA.<\/jats:p>","DOI":"10.1007\/s10741-025-10493-3","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T02:14:52Z","timestamp":1739153692000},"page":"605-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Positron emission tomography in cardiac amyloidosis: current evidence and future directions"],"prefix":"10.1007","volume":"30","author":[{"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Fu","family":"Ferrari Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Genovesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assuero","family":"Giorgetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"17","key":"10493_CR1","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","volume":"27","author":"G Vergaro","year":"2020","unstructured":"Vergaro G, Aimo A, Barison A et al (2020) Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol 27(17):1806\u20131815. https:\/\/doi.org\/10.1177\/2047487319877708","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10493_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1023\/a:1006210913708","volume":"15","author":"K Kodama","year":"1999","unstructured":"Kodama K, Hamada M, Kuwahara T et al (1999) Rest-redistribution thallium-201 myocardial scintigraphic study in cardiac amyloidosis. Int J Card Imag 15(5):371\u2013378. https:\/\/doi.org\/10.1023\/a:1006210913708","journal-title":"Int J Card Imag"},{"issue":"12","key":"10493_CR3","first-page":"2049","volume":"30","author":"H Ohta","year":"1989","unstructured":"Ohta H, Endo K, Kanoh T, Konishi J, Kotoura H (1989) Technetium-99m (V) DMSA uptake in amyloidosis. J Nucl Med 30(12):2049\u20132052","journal-title":"J Nucl Med"},{"issue":"5","key":"10493_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCIMAGING.112.000367","volume":"6","author":"MC Coutinho","year":"2013","unstructured":"Coutinho MC, Cortez-Dias N, Cantinho G et al (2013) Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imag 6(5):627\u2013636. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.000367","journal-title":"Circ Cardiovasc Imag"},{"issue":"4","key":"10493_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/13506129.2020.1769059","volume":"27","author":"A Gimelli","year":"2020","unstructured":"Gimelli A, Aimo A, Vergaro G et al (2020) Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. Amyloid 27(4):237\u2013243. https:\/\/doi.org\/10.1080\/13506129.2020.1769059","journal-title":"Amyloid"},{"issue":"6","key":"10493_CR6","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","volume":"13","author":"MB Musumeci","year":"2020","unstructured":"Musumeci MB, Cappelli F, Russo D et al (2020) Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imag 13(6):1314\u20131321. https:\/\/doi.org\/10.1016\/j.jcmg.2019.10.015","journal-title":"JACC Cardiovasc Imag"},{"issue":"3","key":"10493_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2020.1744553","volume":"27","author":"MC Azevedo Coutinho","year":"2020","unstructured":"Azevedo Coutinho MC, Cortez-Dias N, Cantinho G et al (2020) The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid 27(3):174\u2013183. https:\/\/doi.org\/10.1080\/13506129.2020.1744553","journal-title":"Amyloid"},{"issue":"6","key":"10493_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076\u20131084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10493_CR9","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 42(16):1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"issue":"24","key":"10493_CR10","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maure MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"issue":"6","key":"10493_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11886-020-01284-3","volume":"22","author":"C Gallegos","year":"2020","unstructured":"Gallegos C, Miller EJ (2020) Advances in PET-based cardiac amyloid radiotracers. Curr Cardiol Rep 22(6):40. https:\/\/doi.org\/10.1007\/s11886-020-01284-3","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10493_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s12350-021-02524-x","volume":"29","author":"V Singh","year":"2022","unstructured":"Singh V, Dorbala S (2022) Positron emission tomography for cardiac amyloidosis: timing matters! J Nucl Cardiol 29(2):790\u2013797. https:\/\/doi.org\/10.1007\/s12350-021-02524-x","journal-title":"J Nucl Cardiol"},{"issue":"22","key":"10493_CR13","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.1021\/jm900871v","volume":"52","author":"K Serdons","year":"2009","unstructured":"Serdons K, Van Laere K, Janssen P et al (2009) Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents. J Med Chem 52(22):7090\u20137102. https:\/\/doi.org\/10.1021\/jm900871v","journal-title":"J Med Chem"},{"issue":"11","key":"10493_CR14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11886-024-02114-6","volume":"26","author":"AJ Romero Pab\u00f3n","year":"2024","unstructured":"Romero Pab\u00f3n AJ, Clerc OF, Vijayakumar S, Cuddy SAM, Dorbala S (2024) Recent advances in positron emission tomography radiotracers to image cardiac amyloidosis. Curr Cardiol Rep 26(11):1153\u20131162. https:\/\/doi.org\/10.1007\/s11886-024-02114-6","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10493_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer\u2019s disease with pittsburgh compound-B. Ann Neurol 55(3):306\u2013319. https:\/\/doi.org\/10.1002\/ana.20009","journal-title":"Ann Neurol"},{"issue":"2","key":"10493_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S et al (2013) In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 54(2):213\u2013220. https:\/\/doi.org\/10.2967\/jnumed.111.102053","journal-title":"J Nucl Med"},{"issue":"4","key":"10493_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","volume":"75","author":"SP Lee","year":"2020","unstructured":"Lee SP, Suh HY, Park S et al (2020) Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol 75(4):380\u2013390. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.037","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10493_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, Skibsted Clemmensen T et al (2020) Diagnostic accuracy of [11C]PiB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imag 13(6):1337\u20131347. https:\/\/doi.org\/10.1016\/j.jcmg.2020.02.023","journal-title":"JACC Cardiovasc Imag"},{"issue":"4","key":"10493_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","volume":"27","author":"K Takasone","year":"2020","unstructured":"Takasone K, Katoh N, Takahashi Y et al (2020) Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging. Amyloid 27(4):266\u2013274. https:\/\/doi.org\/10.1080\/13506129.2020.1798223","journal-title":"Amyloid"},{"issue":"9","key":"10493_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/RLU.0000000000003665","volume":"46","author":"X Wang","year":"2021","unstructured":"Wang X, Wang Y, Li J, Huo L, Zhang S (2021) Noninvasive detection of cardiac amyloid with 11C-Pittsburgh compound B PET\/CT and 99mTc-PYP scintigraphy. Clin Nucl Med 46(9):776\u2013778. https:\/\/doi.org\/10.1097\/RLU.0000000000003665","journal-title":"Clin Nucl Med"},{"key":"10493_CR21","doi-asserted-by":"publisher","first-page":"830572","DOI":"10.3389\/fcvm.2022.830572","volume":"9","author":"X Bi","year":"2022","unstructured":"Bi X, Xu B, Liu J et al (2022) Diagnostic value of 11C-PIB PET\/MR in cardiac amyloidosis. Front Cardiovasc Med 9:830572. https:\/\/doi.org\/10.3389\/fcvm.2022.830572","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10493_CR22","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","volume":"63","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Koh Y, Lee HJ et al (2022) Independent prognostic utility of 11C-Pittsburgh Compound B PET in patients with light-chain cardiac amyloidosis. J Nucl Med 63(7):1064\u20131069. https:\/\/doi.org\/10.2967\/jnumed.121.263033","journal-title":"J Nucl Med"},{"issue":"1","key":"10493_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12350-018-1260-5","volume":"27","author":"R Minamimoto","year":"2020","unstructured":"Minamimoto R, Awaya T, Iwama K et al (2020) Significance of 11C-PIB PET\/CT in cardiac amyloidosis compared with 99mTc-aprotinin scintigraphy: a pilot study. J Nucl Med 27(1):202\u2013209. https:\/\/doi.org\/10.1007\/s12350-018-1260-5","journal-title":"J Nucl Med"},{"key":"10493_CR24","doi-asserted-by":"publisher","first-page":"101816","DOI":"10.1016\/j.nuclcard.2024.101816","volume":"33","author":"K Fujioka","year":"2024","unstructured":"Fujioka K, Norikane T, Takami Y et al (2024) Feasibility of PiB positron emission tomography\/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis. J Nucl Cardiol 33:101816. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.101816","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10493_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13506129.2022.2141623","volume":"30","author":"EE Abrahamson","year":"2023","unstructured":"Abrahamson EE, Padera RF, Davies J et al (2023) The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis. Amyloid 30(2):169\u2013187. https:\/\/doi.org\/10.1080\/13506129.2022.2141623","journal-title":"Amyloid"},{"issue":"3","key":"10493_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68(3):319\u2013329. https:\/\/doi.org\/10.1002\/ana.22068","journal-title":"Ann Neurol"},{"issue":"2","key":"10493_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","volume":"43","author":"K Heurling","year":"2016","unstructured":"Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg A (2016) Imaging \u03b2-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imag 43(2):362\u2013373. https:\/\/doi.org\/10.1007\/s00259-015-3208-1","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"11","key":"10493_CR28","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.1002\/14651858.CD012884","volume":"11","author":"G Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez G, Vernooij RW, Fuentes Padilla P et al (2017) 18F PET with flutemetamol for the early diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochr Datab Syst Rev 11(11):12884. https:\/\/doi.org\/10.1002\/14651858.CD012884","journal-title":"Cochr Datab Syst Rev"},{"issue":"8","key":"10493_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/RLU.0000000000000492","volume":"39","author":"R Lhommel","year":"2014","unstructured":"Lhommel R, Sempoux C, Ivanoiu A, Michaux L, Gerber B (2014) Is 18F-flutemetamol PET\/CT able to reveal cardiac amyloidosis? Clin Nucl Med 39(8):747\u2013749. https:\/\/doi.org\/10.1097\/RLU.0000000000000492","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10493_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R (2019) Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography. Ann Nucl Med 33(8):624\u2013628. https:\/\/doi.org\/10.1007\/s12149-019-01372-7","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10493_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","volume":"27","author":"S M\u00f6ckelind","year":"2020","unstructured":"M\u00f6ckelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundstr\u00f6m T (2020) Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid 27(3):191\u2013199. https:\/\/doi.org\/10.1080\/13506129.2020.1760237","journal-title":"Amyloid"},{"issue":"2","key":"10493_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","volume":"29","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, Kessler L, Carpinteiro A et al (2022) 18F-flutemetamol positron emission tomography in cardiac amyloidosis. J Nucl Cardiol 29(2):779\u2013789. https:\/\/doi.org\/10.1007\/s12350-020-02363-2","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10493_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00259-019-04516-z","volume":"47","author":"S Auvity","year":"2020","unstructured":"Auvity S, Tonietto M, Caill\u00e9 F et al (2020) Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. Eur J Nucl Med Mol Imag 47(2):490\u2013501. https:\/\/doi.org\/10.1007\/s00259-019-04516-z","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10493_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"367","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C (2012) Brain amyloid imaging\u2013FDA approval of florbetapir F18 injection. New Engl J Med 367(10):885\u2013887. https:\/\/doi.org\/10.1056\/NEJMp1208061","journal-title":"New Engl J Med"},{"issue":"3","key":"10493_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ et al (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305(3):275\u2013283. https:\/\/doi.org\/10.1001\/jama.2010.2008","journal-title":"JAMA"},{"key":"10493_CR36","doi-asserted-by":"publisher","unstructured":"Park MA et al (2015) 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging 8(8). https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.002954","DOI":"10.1161\/CIRCIMAGING.114.002954"},{"issue":"9","key":"10493_CR37","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J et al (2014) Imaging cardiac amyloidosis: a pilot study using 1\u2078F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imag 41(9):1652\u20131662. https:\/\/doi.org\/10.1007\/s00259-014-2787-6","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10493_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","volume":"2","author":"DR Osborne","year":"2015","unstructured":"Osborne DR, Acuff SN, Stuckey A, Wall JS (2015) A routine PET\/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-Florbetapir. Front Cardiovasc Med 2:23. https:\/\/doi.org\/10.3389\/fcvm.2015.00023","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10493_CR39","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jcmg.2024.05.002","volume":"17","author":"OF Clerc","year":"2024","unstructured":"Clerc OF, Datar Y, Cuddy SAM et al (2024) Prognostic value of left ventricular 18F-florbetapir uptake in systemic light-chain amyloidosis. JACC Cardiovasc Imag 17(8):911\u2013922. https:\/\/doi.org\/10.1016\/j.jcmg.2024.05.002","journal-title":"JACC Cardiovasc Imag"},{"issue":"5","key":"10493_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/ehjci\/jead350","volume":"25","author":"Y Datar","year":"2024","unstructured":"Datar Y, Clerc OF, Cuddy SAM et al (2024) Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography\/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis. Eur Heart J Cardiovasc Imag 25(5):687\u2013697. https:\/\/doi.org\/10.1093\/ehjci\/jead350","journal-title":"Eur Heart J Cardiovasc Imag"},{"issue":"4","key":"10493_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","volume":"25","author":"R Manwani","year":"2018","unstructured":"Manwani R, Page J, Lane T et al (2018) A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid 25(4):247\u2013252. https:\/\/doi.org\/10.1080\/13506129.2018.1552852","journal-title":"Amyloid"},{"issue":"1","key":"10493_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H (2015) Beta-amyloid imaging with florbetaben. Clin Transl Imag 3(1):13\u201326. https:\/\/doi.org\/10.1007\/s40336-015-0102-6","journal-title":"Clin Transl Imag"},{"issue":"11","key":"10493_CR43","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","volume":"57","author":"WP Law","year":"2016","unstructured":"Law WP, Wang WY, Moore PT, Mollee PN, Ng AC (2016) Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study. J Nucl Med 57(11):1733\u20131739. https:\/\/doi.org\/10.2967\/jnumed.115.169870","journal-title":"J Nucl Med"},{"issue":"1","key":"10493_CR44","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","volume":"8","author":"L Baratto","year":"2018","unstructured":"Baratto L, Park SY, Hatami N et al (2018) 18F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition. EJNMMI Res 8(1):66. https:\/\/doi.org\/10.1186\/s13550-018-0425-1","journal-title":"EJNMMI Res"},{"issue":"7","key":"10493_CR45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, Ihne S, Brumberg J et al (2019) Detection of cardiac amyloidosis with 18F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imag 46(7):1407\u20131416. https:\/\/doi.org\/10.1007\/s00259-019-04290-y","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10493_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","volume":"14","author":"D Genovesi","year":"2021","unstructured":"Genovesi D, Vergaro G, Giorgetti A, Marzullo P, Scipioni M, Santarelli MF, Pucci A, Buda G, Volpi E, Emdin M (2021) [18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imag 14(1):246\u2013255. https:\/\/doi.org\/10.1016\/j.jcmg.2020.05.031","journal-title":"JACC Cardiovasc Imag"},{"issue":"4","key":"10493_CR47","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","volume":"29","author":"MF Santarelli","year":"2022","unstructured":"Santarelli MF, Genovesi D, Scipioni M et al (2022) Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images. J Nucl Cardiol 29(4):1919\u20131932. https:\/\/doi.org\/10.1007\/s12350-021-02608-8","journal-title":"J Nucl Cardiol"},{"issue":"7","key":"10493_CR48","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s10554-021-02190-7","volume":"37","author":"MF Santarelli","year":"2021","unstructured":"Santarelli MF, Genovesi D, Positano V et al (2021) Deep-learning-based cardiac amyloidosis classification from early acquired pet images. Int J Cardiovasc Imag 37(7):2327\u20132335. https:\/\/doi.org\/10.1007\/s10554-021-02190-7","journal-title":"Int J Cardiovasc Imag"},{"key":"10493_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeae332","author":"G Vergaro","year":"2024","unstructured":"Vergaro G, Aimo A, Genovesi D et al (2024) Estimated total amyloid burden from 18F-florbetaben PET predicts all-cause mortality in light-chain cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. https:\/\/doi.org\/10.1093\/ehjci\/jeae332","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"10493_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2967\/jnmt.119.234336","volume":"48","author":"K Ahuja","year":"2020","unstructured":"Ahuja K, Sotoudeh H, Galgano SJ et al (2020) 18F-sodium fluoride PET: history, technical feasibility, mechanism of action, normal biodistribution, and diagnostic performance in bone metastasis detection compared with other imaging modalities. J Nucl Med Technol 48(1):9\u201316. https:\/\/doi.org\/10.2967\/jnmt.119.234336","journal-title":"J Nucl Med Technol"},{"issue":"4","key":"10493_CR51","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s12350-015-0287-0","volume":"23","author":"A Van Der Gucht","year":"2016","unstructured":"Van Der Gucht A, Galat A, Rosso J et al (2016) [18F]-NaF PET\/CT imaging in cardiac amyloidosis. J Nucl Cardiol 23(4):846\u2013849. https:\/\/doi.org\/10.1007\/s12350-015-0287-0","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"10493_CR52","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s12350-017-0799-x","volume":"25","author":"R Morgenstern","year":"2018","unstructured":"Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S (2018) 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol 25(5):1559\u20131567. https:\/\/doi.org\/10.1007\/s12350-017-0799-x","journal-title":"J Nucl Cardiol"},{"issue":"24","key":"10493_CR53","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2016.09.953","volume":"68","author":"MG Trivieri","year":"2016","unstructured":"Trivieri MG, Dweck MR, Abgral R et al (2016) 18F-sodium fluoride PET\/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol 68(24):2712\u20132714. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.953","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10493_CR54","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s12350-019-01885-8","volume":"28","author":"M Abulizi","year":"2021","unstructured":"Abulizi M, Sifaoui I, Wuliya-Gariepy M et al (2021) 18F-sodium fluoride PET\/MRI myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol 28(4):1586\u20131595. https:\/\/doi.org\/10.1007\/s12350-019-01885-8","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"10493_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12350-019-01675-2","volume":"28","author":"P Martineau","year":"2021","unstructured":"Martineau P, Finnerty V, Giraldeau G et al (2021) Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis. J Nucl Cardiol 28(1):209\u2013218. https:\/\/doi.org\/10.1007\/s12350-019-01675-2","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10493_CR56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12350-020-02356-1","volume":"29","author":"JPM Andrews","year":"2022","unstructured":"Andrews JPM, Trivieri MG, Everett R et al (2022) 18F-fluoride PET\/MR in cardiac amyloid: a comparison study with aortic stenosis and age- and sex-matched controls. J Nucl Cardiol 29(2):741\u2013749. https:\/\/doi.org\/10.1007\/s12350-020-02356-1","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10493_CR57","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s12350-020-02425-5","volume":"29","author":"LX Zhang","year":"2022","unstructured":"Zhang LX, Martineau P, Finnerty V et al (2022) Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis. J Nucl Cardiol 29(3):1132\u20131140. https:\/\/doi.org\/10.1007\/s12350-020-02425-5","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"10493_CR58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/ph16040629","volume":"16","author":"EB Martin","year":"2023","unstructured":"Martin EB, Stuckey A, Powell D et al (2023) Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide 124I\u2013p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET\/CT imaging. Pharmaceuticals 16(4):629. https:\/\/doi.org\/10.3390\/ph16040629","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10493_CR59","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall JS, Martin EB, Lands R et al (2023) Cardiac amyloid detection by PET\/CT imaging of iodine (124I) evuzamitide (124I\u2013p5+14): a phase 1\/2 study. JACC Cardiovasc Imag 16(11):1433\u20131448. https:\/\/doi.org\/10.1016\/j.jcmg.2023.08.009","journal-title":"JACC Cardiovasc Imag"},{"issue":"11","key":"10493_CR60","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","volume":"16","author":"OF Clerc","year":"2023","unstructured":"Clerc OF, Cuddy SAM, Robertson M et al (2023) Cardiac amyloid quantification using 124I-evuzamitide (124I\u2013P5+14) versus 18F-florbetapir: a pilot PET\/CT study. JACC Cardiovasc Imag 16(11):1419\u20131432. https:\/\/doi.org\/10.1016\/j.jcmg.2023.07.007","journal-title":"JACC Cardiovasc Imag"},{"issue":"2","key":"10493_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2023.2286427","volume":"31","author":"R Lands","year":"2024","unstructured":"Lands R, Martin EB, Powell D et al (2024) Longitudinal PET\/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis. Amyloid\u202f: the international journal of experimental and clinical investigation\u202f: the official journal of the International Society of Amyloidosis 31(2):148\u2013149. https:\/\/doi.org\/10.1080\/13506129.2023.2286427","journal-title":"Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis"},{"issue":"1","key":"10493_CR62","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF et al (2019) State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 26(1):158\u2013173. https:\/\/doi.org\/10.1007\/s12350-018-01552-4","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"10493_CR63","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Cuddy S, Falk RH (2020) How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imag 13(6):1368\u20131383. https:\/\/doi.org\/10.1016\/j.jcmg.2019.07.015","journal-title":"JACC Cardiovasc Imag"},{"issue":"1","key":"10493_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","volume":"27","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Ha S, Kim YI (2020) Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis. J Nucl Cardiol 27(1):123\u2013132. https:\/\/doi.org\/10.1007\/s12350-018-1365-x","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"10493_CR65","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/J.JCMG.2020.02.025","volume":"13","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM et al (2020) Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease? JACC Cardiovasc Imag 13(6):1325\u20131336. https:\/\/doi.org\/10.1016\/J.JCMG.2020.02.025","journal-title":"JACC Cardiovasc Imag"},{"issue":"13","key":"10493_CR66","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","volume":"79","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi C et al (2022) Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC State-of-the-Art Review. J Am Coll Cardiol 79(13):1288\u20131303. https:\/\/doi.org\/10.1016\/j.jacc.2022.01.036","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10493_CR67","doi-asserted-by":"publisher","first-page":"102733","DOI":"10.1016\/j.cpcardiol.2024.102733","volume":"49","author":"A Albulushi","year":"2024","unstructured":"Albulushi A, Al Hajri R, Hovseth C et al (2024) Advancements and challenges in cardiac amyloidosis imaging: a comprehensive review of novel techniques and clinical applications. Curr Probl Cardiol 49(9):102733. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102733","journal-title":"Curr Probl Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10493-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:18:52Z","timestamp":1744359532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10493-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["10493"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10493-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"31 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}